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Six dimensions of research trial acceptability: how much, what, when, in what 1 
circumstances, to whom and why?  2 
 3 
Abstract 4 
  5 
Ethics guidelines emphasise that research should be acceptable to the people 6 
invited to take part. However, acceptability is subjective and dependent on context, 7 
complicating its assessment and use as an ethical standard.  8 
 9 
This paper examines the concept of acceptability in relation to parents’ perspectives 10 
on a paediatric vaccine trial in Malawi. We examined decisions on participation and 11 
experiences of the trial through interviews with parents in 41 households invited to 12 
enrol their children, and through participant observation of trial processes. Fieldwork 13 
took place in Chikwawa, Southern Malawi from February – October 2016. 14 
 15 
Parents were not neatly split between those who saw the trial as acceptable and 16 
those who did not; instead there were mixed and changing feelings among parents 17 
who enrolled their children, and among those who withdrew or did not take part. 18 
Some parents agreed to participate but had concerns about the trial, while others 19 
expressed satisfaction with the trial but still did not take part. 20 
 21 
These experiences indicate substantial variation in the nature of acceptance. We 22 
describe these variations in relation to six dimensions of acceptability: how 23 
acceptable the trial is, what aspects are acceptable, changes over time, 24 
circumstances affecting acceptability, variations between people, and reasons for 25 
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participation or non-participation. 26 
 27 
The findings illustrate the difficulty of determining whether a trial is sufficiently 28 
acceptable to potential participants. We suggest that clarifying definitions of 29 
acceptability and examining how acceptability varies in degree, between trial 30 
components, over time, and between people and contexts may help researchers 31 
generate more nuanced descriptions of acceptability that support responsive and 32 
ethical trial design. 33 
 34 
Keywords: 35 
acceptability, ethics, community, Malawi, medical research  36 
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Background 37 
 38 
The acceptability of research to invited participants is essential for ethical practice.  39 
WHO identifies “acceptability to participants” as a key ethical issue in study design 40 
(WHO, 2014, p. 6), and the UK Health Research Authority suggests that defining 41 
“what is acceptable to participants” helps “make research ethical” (Involve, 2016, p. 42 
1).Understanding and enhancing acceptability among the people invited to 43 
participate is an important function of community engagement (CIOMS, 2016; 44 
Nuffield Council on Bioethics, 2015): community input helps “in ensuring that 45 
protocol designs and procedures are […] acceptable to the trial population”, in turn 46 
“improving recruitment, retention, adherence, and other trial outcomes” 47 
(UNAIDS/AVAC, 2011, pp. 44, 20). As such, as well as holding ethical significance, 48 
acceptability affects study feasibility: adequate recruitment is unlikely if potential 49 
participants see procedures as unacceptable (Feeley et al., 2009).  50 
 51 
While the importance of acceptability seems clear, its meaning is more ambiguous; 52 
indeed, the idea of acceptability among people affected by research has been 53 
criticised as “extremely vague” (Macdonald, 2017, p. 32). Dictionary definitions 54 
include both positive and negative situations: acceptable is defined as both 55 
“welcome, pleasing” and “barely satisfactory or adequate” (Merriam-Webster, 56 
2017a), while accept can mean “receive willingly” or “endure without protest” 57 
(Merriam-Webster, 2017b). Discussions about the acceptability of research to invited 58 
participants often lack explicit definitions (Feeley et al., 2009). Some analyses 59 
equate acceptance with participation, contrasting this with refusal to participate, as in 60 
“deciding whether to accept or decline the research” (Mfutso-Bengo et al., 2008, p. 61 
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58; other examples include Gysels et al., 2008; Fayter et al., 2007; Moynihan et al., 62 
2012). However, these categories of participating and refusing can hide substantial 63 
variation in views on study procedures (Fairhead et al., 2004). Further, researchers 64 
often discuss promoting “acceptance” when they mean ensuring “tolerance” or 65 
“avoiding organised opposition” (Lavery, 2017). To accommodate this variation in 66 
meaning, we adopt a working definition of acceptability as a perception among 67 
invited participants that the research design is, to varying extents, “favourab[le]” 68 
(Feeley et al., 2009, p. 86), “agreeable, palatable, or satisfactory” (Proctor et al., 69 
2010, p. 67). This definition reflects our focus on acceptability of study designs to 70 
participants as ethically significant. 71 
 72 
As well as ambiguity regarding its meaning, assessment of acceptability is 73 
complicated by subjectivity, variability and dependence on context. Acceptability is 74 
not a fixed property of a trial or particular research procedure, but rather determined 75 
by individual perceptions, and shaped by personal and social contexts. This 76 
influence of context is discussed explicitly in some accounts of views on research 77 
among participant communities (Fairhead et al., 2004; Kingori, 2015), and suggested 78 
by studies on willingness to participate (Cunningham et al., 2018; Gamble et al., 79 
2012; Otwombe et al., 2011; Trauth et al., 2000) and reasons for participation or 80 
refusal (Gysels et al., 2008; Strömmer et al., 2018) that describe varied perspectives 81 
among target participants. However, the significance of contextual variability is 82 
explored more extensively in literature on acceptability of health interventions. As 83 
this literature suggests, different individual, household or group circumstances and 84 
priorities generate varied perceptions of acceptability (Heise, 1997; Montgomery et 85 
al., 2010). Research on health interventions also shows that acceptability can 86 
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change over time, for example shifting through social interactions (Cohn, 2016) or 87 
with experience (Dyer et al., 2016). Acceptability is also relative, such that views of a 88 
particular health intervention depend on the perceived suitability of any alternative 89 
interventions (Heise, 1997; Hyder and Morrow, 2006; Mcintyre et al., 2009). Finally, 90 
the degree of acceptability varies, ranging from high demand to ambivalence (SAGE 91 
Working Group on Vaccine Hesitancy, 2014).  92 
 93 
Although existing literature points to these variations in acceptability, the concept of 94 
acceptability has not been a specific focus in discussions about research 95 
participation. We lack frameworks for examining acceptability among invited 96 
participants, and reviews of research on trial participation and acceptability call for 97 
more in-depth analysis and understanding of individual variation (O’Cathain et al., 98 
2014; Ross et al., 1999). Some approaches to assessing acceptability may miss 99 
important variations in and reasons behind invited participants’ perceptions. For 100 
example, assessing acceptability based on consent to enrol or using single timepoint 101 
questionnaires (e.g. Richards et al., 2014; Stead et al., 2005; Wallace et al., 2018) 102 
may overlook different degrees of acceptability, changes over time, or contexts 103 
affecting decisions on enrolment. Qualitative reports may also neglect underlying 104 
contexts or describe only limited areas of variation (for example, between individuals 105 
rather than over time) (e.g. Crawley et al., 2013; Gafos et al., 2017). Given the 106 
ethical importance of acceptability and its ambiguity, further work to clarify this 107 
concept may support more nuanced investigation of participant perceptions to inform 108 
responsive trial design. 109 
     110 
Our research examines acceptability in the context of a paediatric influenza vaccine 111 
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trial in Malawi. We explore parents’ decisions about enrolling their children and 112 
reasons behind these decisions, perceptions of the trial, and variation in acceptability 113 
between trial procedures, over time and between contexts and people. Our aim is to 114 
deepen understanding of the acceptability of research to potential participants, and 115 
to suggest directions for future assessment of acceptable trial design.  116 
 117 
The vaccine trial examined whether malaria infection affects immune response to 118 
influenza vaccine in children (the FLUVAC trial, details in Peterson, 2016). The trial 119 
took place in Chikwawa, a rural district in Southern Malawi where under 5 mortality is 120 
62 per 1000 live births and the poverty rate is 82% (compared to 73 per 1000 and 121 
51% for Malawi overall, Government of Malawi, 2012; National Statistical Office, 122 
2017). Approximately 1300 children aged 6 to 59 months were recruited. 123 
Participation involved three main appointments, spaced one month apart. Children 124 
received the influenza vaccine at the first two appointments, and had samples taken 125 
at all three appointments, including a venous blood sample to measure influenza 126 
serology, a finger prick blood sample to test for the malaria parasite (not in real time), 127 
and stool samples from a subset of children. A point of care rapid diagnostic test for 128 
malaria was administered to febrile children to guide treatment. Trial teams rotated 129 
between 28 villages, spending approximately two weeks at a time in each village and 130 
returning one month later for follow-up visits.  131 
 132 
Given the age of child participants, enrolment was decided by parents. Fieldworkers 133 
and community volunteers approached parents in their homes and invited them to 134 
visit a study tent assembled in each village, where further information was provided. 135 
Trial staff gave parents an information sheet describing procedures, risks (potential 136 
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side effects and discomfort from the vaccine and blood samples) and benefits 137 
(reduced risk from influenza, malaria treatment if tested positive, and the population 138 
health benefit of additional evidence on influenza vaccination) (see supplementary 139 
file 1) [insert online file 1 here]. Procedures, risks and benefits were also explained 140 
verbally, with time for questions. Although parents were not vaccinated, they were 141 
required to participate actively in the trial by answering questionnaires on household 142 
circumstances and their own health status, completing an adverse event diary, and 143 
accompanying their child during study appointments. The trial protocol referred to 144 
parents as participants, and consent forms completed by parents indicated their 145 
agreement “to take part in the above study”. Parents also described themselves as 146 
participating or withdrawing during interviews. Given this role, we consider parents 147 
as participants or non-participants, not just as enrolling their children. 148 
 149 
Methods 150 
We used qualitative research to examine parents’ experiences and decisions about 151 
trial participation. We conducted interviews with parents in 41 households invited to 152 
enrol their children, including parents who enrolled their child (21), who withdrew (9), 153 
and who did not participate (11). Most interviews involved the main carer (usually the 154 
mother), but in some cases a wife and husband were interviewed together because 155 
both wanted to be interviewed. With these joint interviews, we took care to 156 
encourage responses from both parents. Interviews were divided between nine 157 
villages where the trial took place, selected to cover variations in circumstances such 158 
as proximity to health centres, time points during the trial, and levels of uptake as 159 
reported by trial staff. Some parents were interviewed a few days after the first 160 
appointment, others midway through participation, and others after completion or 161 
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withdrawal, providing a range of experiences. Repeat interviews were conducted 162 
with three parents who were initially interviewed shortly after their first trial 163 
appointment, including one who withdrew and two who remained in the trial, to 164 
understand any changes in their experiences over time. Topic guides covered 165 
experience of the trial, decisions regarding participation, information about the trial 166 
purpose and procedures, perceived benefits and drawbacks, and issues that might 167 
affect engagement such as previous research experience (see Supplementary file 2) 168 
[INSERT LINK TO ONLINE FILE 2]. Interviews lasted approximately one hour and 169 
were conducted in Chichewa by an experienced qualitative researcher (MP). Audio 170 
recordings were transcribed verbatim and translated into English. 171 
 172 
We also conducted participant observation of trial processes. This involved 173 
accompanying fieldworkers as they approached parents, observing informed consent 174 
procedures, attending community meetings about the trial, and holding informal 175 
discussions with trial staff and community members in trial villages. Observation was 176 
undertaken primarily by a Malawian researcher of equivalent seniority to trial staff 177 
(MP), with some visits by KG. Notes were taken during observation and expanded 178 
the same day. 179 
 180 
Data analysis was ongoing throughout fieldwork. The research team regularly 181 
discussed emerging issues to identify aspects for further investigation, including 182 
searching for conflicting data or alternative explanations (Patton, 2002). Later 183 
analysis involved thematic coding (Gibbs, 2008) of observation notes and interview 184 
transcripts in NVivo, using a combination of emerging themes (such as concern 185 
around blood samples) and broader categories related to the research objective 186 
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(such as reasons for participation). Initial transcripts were coded independently by 187 
KG and MP, and compared to generate a common coding frame that was then 188 
adapted with further coding (see Supplementary file 3) [INSERT LINK TO ONLINE 189 
FILE 3]. We used qualitative tables that displayed codes against cases to compare 190 
perceptions between parents, and memos to capture emerging ideas (Gibbs, 2008). 191 
Interview and observation data were compared to check and extend interpretations.  192 
 193 
During analysis, we identified multiple variations in acceptability, for example 194 
between contexts and over time. These variations were identified through a 195 
combination of reviewing coding, looking across cases and reading individual cases. 196 
For example, material coded as ‘reasons for withdrawal’ and ‘regret’ pointed to 197 
changes in acceptability over time, while reviewing the qualitative tables helped to 198 
indicate variations in acceptability between individual contexts. Initial ideas about 199 
variations were then explored further through re-reading coded sections and 200 
transcripts to check and develop our understanding. We progressively refined our 201 
categorisation of these variations to identify six dimensions of acceptability: the 202 
degree of acceptability, what is acceptable, when a trial is acceptable, variation 203 
between circumstances, variation between people, and reasons for participation. 204 
This final categorisation was developed through a process of logical analysis 205 
(Patton, 2002) that drew on variations identified inductively, and variations to which 206 
we were sensitised from literature on acceptability and our experience with the realist 207 
evaluation emphasis on “what works, how, why, for whom, to what extent and in 208 
what circumstances, in what respect and over what duration” (Wong et al., 2017, p. 209 
21). We worked back and forth between these sensitising concepts and our data to 210 
develop a set of dimensions that matched parents’ experiences (Patton, 2002). The 211 
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realist motto helped reshape variations identified inductively into distinct categories, 212 
but our use of realist approaches was restricted to considering this pattern of 213 
outcomes, rather than steps such as explicitly identifying mechanisms.  214 
 215 
The study was approved by the Liverpool School of Tropical Medicine and Malawi 216 
College of Medicine research ethics committees. All interview and observation 217 
participants received a written information sheet and the study purpose, 218 
requirements, benefits and risks were also explained verbally. All participants 219 
provided written informed consent.  220 
 221 
  222 
Results 223 
Narratives about the trial revealed diverse views among parents who enrolled their 224 
children, and among those who withdrew or did not take part. We draw out these 225 
variations in acceptability in relation to the six dimensions identified during analysis: 226 
how acceptable the trial is, what aspects are acceptable, changes over time, 227 
circumstances affecting acceptability, variations between people, and reasons for 228 
participation or non-participation. These six dimensions overlap and interact. For 229 
example, individual circumstances affect who sees a trial as acceptable, changing 230 
circumstances affect when a trial is acceptable, and the degree of acceptability is 231 
linked to reasons for participation. 232 
 233 
How acceptable is the trial? Tolerance or satisfaction 234 
Parents who enrolled their children in the trial reported contrasting levels of 235 
satisfaction. Some were highly enthusiastic about all trial components:  236 
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I finished the study without any issues. The child didn’t experience any problems, 237 
from the start to the end. I found it useful and I was happy with it. (Mother, 238 
participant, ID18) 239 
The husband of this woman was equally positive, to the extent that he encouraged 240 
further research: 241 
If they were considering another phase of the study, based on my experience they 242 
should go ahead with it … If the child is eligible, I would enrol again. (Father, 243 
participant, ID18) 244 
Other parents participated throughout but saw the trial as problematic and enrolled 245 
their children reluctantly. For example, one mother was concerned that blood 246 
samples would make her child sick: 247 
I don’t think the process is good - you go today and they collect blood, you go 248 
another day and they do the same thing, so I see that they will drain blood from 249 
her body. … So we just go there, but we are not happy deep inside our hearts. 250 
(Mother, participant ID30)  251 
Indeed, some parents had distressing experiences of the trial but still continued 252 
participating. A particular concern was difficulty encountered by trial staff in collecting 253 
blood from younger children, which sometimes meant needles were inserted several 254 
times:  255 
When you go, the child is pricked all over to find the veins, and that really affected 256 
me - pricking here, pricking there, and the child was just crying, to the point where 257 
I ran out of the tent. (Mother, participant, ID16) 258 
Despite this experience, this mother planned to continue participating because she 259 
thought the trial would benefit her child’s health, saying that at the next appointment, 260 
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“I will just be strong”.   261 
 262 
These contrasting experiences suggest a continuum of acceptability, from high levels 263 
of enthusiasm through to tolerance and reluctant participation. They also highlight a 264 
distinction between agreement to participate and satisfaction with trial procedures, to 265 
which we return later. 266 
 267 
 268 
What aspects of the trial do people see as acceptable? Mixed views and 269 
misunderstandings 270 
Most parents saw the trial as neither wholly acceptable or unacceptable; they liked 271 
some components and disliked others. For example, many parents appreciated 272 
access to the vaccine and other health services, but had concerns about blood 273 
samples, side effects, or lack of individual test results. 274 
This study has good parts and bad parts. The bad part is that some children fall 275 
sick after being vaccinated. The good part is that whenever the child has flu, she 276 
will have it but not very badly because she received the vaccine. (Mother, 277 
participant, ID22) 278 
I participated because the study will protect the child’s body, but the issue where 279 
we are not getting along with them is that we still haven’t received the results from 280 
the blood they collected. (Mother, participant, ID34) 281 
Those who withdrew or did not take part also had mixed views, seeing potential 282 
benefits alongside their concerns. For example, one couple who withdrew due to 283 
fears about blood samples and perceptions of inadequate assistance in the event of 284 
side effects also described positive aspects of the trial: 285 
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Although we withdrew, being in the study had benefits. The vaccine could prevent 286 
diseases that the child might have. … We also missed out on the mosquito nets. 287 
(Father, withdrew, ID41) 288 
Decisions about overall acceptability and participation involved balancing positive 289 
and negative components; a judgement that the trial was welcome or that 290 
participation was worthwhile did not mean parents saw all aspects as appropriate. 291 
 292 
Examining what parents liked or disliked about the trial also suggested that 293 
assessments sometimes reflected misconceptions of trial procedures. Despite 294 
provision of information through community engagement and consent procedures, 295 
assumptions were made, rumours circulated and some people enrolled because 296 
they expected to gain benefits that would not actually be offered. For example, the 297 
information sheet did not indicate feedback of individual test results, but as illustrated 298 
above, feedback was assumed by many parents. Similarly, one woman explained 299 
that she wanted to enrol because she thought participants would receive a solar 300 
stove, alongside the mosquito net that was actually provided: 301 
People said your friends are going to receive mosquito nets and solar stoves, so 302 
you will be jealous if you don’t take part. So I thought I should not be the only one 303 
not getting those things, I will take part no matter what! (Mother, non-participant, 304 
ID14) 305 
As well as misinformation about trial benefits, there were misconceptions regarding 306 
risks of both participation and refusal. This mother’s wish to enrol also stemmed from 307 
an unfounded concern that refusing might restrict future healthcare access: 308 
I went to the study tent because I thought that if I don’t take part, when I take my 309 
child to the hospital with a fever they will send me away. (Mother, non-participant, 310 
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ID14) 311 
Others viewed the trial negatively because they believed it involved procedures that 312 
were not involved. For example, reflecting long-standing concerns around use of 313 
blood in Malawi and similar settings (Ashforth, 2014; Geissler and Pool, 2006; 314 
Schmidt, 2009), some parents saw the trial as unacceptable because they thought 315 
researchers might sell blood taken as samples: 316 
I refused because some people said the blood they were collecting would be sold. 317 
(Mother, non-participant, ID40)  318 
In these examples, it is perceived rather than actual trial procedures that parents 319 
consider beneficial or problematic, complicate assessment of acceptability. 320 
 321 
 322 
When is the study acceptable? Reassurance and regret  323 
Views of the trial changed over time as parents gained new information and 324 
experiences of the study. Some people became increasingly positive when they 325 
learnt more about procedures or when anticipated problems did not materialise. For 326 
example, one father explained that his initial anxiety about side effects faded when 327 
his child remained healthy:  328 
Joining a strange study with no knowledge of its outcomes leaves you wondering, 329 
- “what are we going to see?” The heart always questions - “won’t this be 330 
dangerous for the child’s health?” But as we never experienced any of that, we’re 331 
positive about the study, and that’s why we went there again. (Father, participant, 332 
ID18) 333 
A similar increase in enthusiasm was expressed by some parents who decided not 334 
to participate and subsequently felt this decision was based on misinformation. For 335 
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example, one mother was afraid to participate after hearing about children fainting 336 
following blood draws, but she later decided these rumours were untrue and wished 337 
she had enrolled.  338 
What disturbed me was that people said another child’s blood was completely 339 
finished … I listened to what others were saying and didn’t go there with the child. 340 
These were lies and I know we made the wrong choice. (Mother, non-participant, 341 
ID40) 342 
Other participants became less satisfied as they learnt more about the trial or when 343 
their expectations went unmet. For example, the participants who expected to 344 
receive individual blood test results were disappointed when results were not 345 
provided. Others saw the trial as increasingly unacceptable because they felt 346 
children experienced side effects. For some, this led to withdrawal: 347 
When I came back home, my child had fever and diarrhoea, she was vomiting and 348 
her body was swollen. … When the researchers visited me to go for a second 349 
visit, I refused – I told them ‘my child fell sick when I took her there, should I go 350 
again given that they will collect blood and my child’s body will become swollen? 351 
No, it’s better to stay at home.’ So I dropped out. (Mother, withdrew, ID36) 352 
These feelings of reassurance and regret show how acceptability can change over 353 
time as new information and experiences overturn previous ideas and surpass or 354 
disappoint expectations. 355 
 356 
 357 
In what circumstances is the trial acceptable? Internal and external conditions 358 
Perceptions of the trial were shaped by conditions within the trial and wider contexts. 359 
The influence of internal trial conditions is illustrated in the previous discussion of 360 
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changing acceptability over time: acceptability of blood samples depended partly on 361 
other trial procedures, including provision of test results. Other conditions affecting 362 
sample acceptability included adequate explanation through community 363 
engagement, assistance in the event of side effects and sufficient compensation. On 364 
the latter, one mother felt parents should receive money rather than the fruit squash 365 
and biscuits that were provided:  366 
Half a bottle of squash is not enough based on how they are collecting blood. … 367 
Half a bottle is very little, they are robbing us. If they were giving us money to buy 368 
food, it would have been better. (Mother, participant, ID19) 369 
The same mother explained that she happily provided blood samples in a previous 370 
study because participants received soap and transport money; different 371 
circumstances meant a procedure was acceptable in one study but not another. 372 
 373 
Beyond the trial, wider socioeconomic, cultural and health contexts also affected 374 
views of trial benefits and disadvantages. For example, several parents concerned 375 
about blood samples mentioned risks of anaemia or thought children would have 376 
insufficient blood, perhaps reflecting a disease context with high levels of anaemia 377 
(National Statistical Office, 2017), and a cultural understanding of blood as 378 
containing the life force (Kaspin, 1996). A context of limited access to healthcare 379 
also shaped views of the trial, and made the opportunity to receive assistance from 380 
health workers in the village an important benefit of participation:  381 
Because we are in a remote area, transport is a problem. Whenever she falls sick 382 
we worry, saying ‘what are we going to do? We don’t have money’, and you just 383 
move up and down looking for transport … If the doctors have left the hospital and 384 
come here, it’s an opportunity for us - whenever we have a problem, they are 385 
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going to help us. (Mother, participant, ID06) 386 
Trial staff noted that recruitment was sometimes harder in villages close to health 387 
centres because healthcare access was relatively easy, reducing the value of 388 
services provided through the trial. Again, a study perceived as acceptable in one set 389 
of circumstances may be unacceptable in another context.  390 
  391 
 392 
Who sees the trial as acceptable? Individual contexts and perceptions  393 
Previous sections indicate varied views of the trial, with some parents seeing it as a 394 
welcome opportunity, and others as risky or unfair. These different views result partly 395 
from different individual contexts, reflecting the influence of circumstances on 396 
acceptability. To take one aspect, parents’ previous research experience affected 397 
their views of the trial. For example, one mother wanted to enrol her child in the 398 
vaccine trial because she felt another of her children was saved through previous 399 
research:    400 
When he was seriously ill, the malaria researchers registered him in their study. 401 
He went there and was tested and he was given medicine and they followed him 402 
until he got well. … With this study, I didn’t even consider refusing because maybe 403 
it is one way that my child can be helped, the way her friend was helped. (Mother, 404 
participant, ID06) 405 
In contrast, another mother decided against enrolling her child due to negative 406 
previous research experience: 407 
I participated in research before when I was pregnant. … I experienced such a 408 
challenge. I would feel weak and fail to walk. … I thought the child might 409 
experience what I experienced - that’s why I said I would not enrol the child. 410 
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(Mother, non-participant, ID11) 411 
These individual experiences affect perceived risks and benefits, contributing to 412 
variations in who sees the trial as acceptable.  413 
 414 
 415 
Why do people take part or not? Distinguishing participation and acceptability 416 
The reluctant participation noted among some parents indicates a distinction 417 
between agreeing to participate and seeing the trial positively. This distinction was 418 
further apparent when examining reasons for participation and non-participation. 419 
Sometimes enrolment or withdrawal was based on decisions about trial benefits and 420 
risks, including aspects previously mentioned such as protection from flu, medical 421 
assistance and material compensation, or side effects, suspicion about blood 422 
samples and inadequate compensation. However, sometimes reasons for 423 
participating or not participating did not involve views of the trial. For example, some 424 
parents intended to participate but arrived at the study tent after recruitment had 425 
finished: 426 
I went to the farm to sow first … When I went there with the child the doctor said 427 
‘you are late’ … I really wanted to participate but I was told that it is done. (Mother, 428 
non-participant, ID29) 429 
Other parents wanted to participate but were stopped by other people. For example, 430 
several women withdrew due to pressure from male partners: 431 
This study is going well and we welcome it in our village. If there is a problem, it is 432 
between me and my husband. … I tried to convince him as I had already started 433 
the study, but he said ‘no don’t go there again’. So as he is the family head, I just 434 
said ‘OK, I won’t go again’. (Mother, withdrew, ID26) 435 
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Another mother explained that she and her husband thought the study was beneficial 436 
but community elders advised them to withdraw: 437 
People said a child in another village died because of the blood collection, so be 438 
careful or your child will also die. … So we just left, thinking that if we insist on 439 
continuing and something happens, people will point at us and say ‘we told you 440 
but you didn’t listen’. … We thought we should not disagree with the elders. …So 441 
we just left, but we thought the study was good. (Mother, withdrew, ID03) 442 
 443 
In contrast, for some parents pressure from other people compelled participation. For 444 
example, one couple initially enrolled to avoid criticism from the village chief: 445 
The headman said ‘I will visit the homes of those who don’t go, so they can 446 
explain to me why they didn’t go.’  … Although he might not do anything, he would 447 
think we are being rude. (Father, withdrew, ID33) 448 
Another mother explained that she wanted to withdraw, but remained in the trial due 449 
to persuasion from the trial team and neighbours:  450 
They said it’s not good to drop out of something you have already started … So I 451 
went, but I wanted to tear the papers [trial documents] so I could tell them they 452 
were soaked in the rain. … If I hadn’t started, I would have left. (Mother, 453 
participant, ID19) 454 
Others continued to participate due to a sense of obligation and feeling they could 455 
not withdraw after agreeing to enrol. For example, one mother only understood that 456 
blood samples would be taken when she entered the study tent, at which point she 457 
felt it was too late to change her mind:  458 
They asked whether you are willing to participate, and when we said yes and 459 
entered the tent, that’s when we saw they were collecting blood. So given that we 460 
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had already accepted, how could we refuse?  (Mother, participant ID30) 461 
 462 
These examples all involve situations where people’s decisions about participation 463 
did not match their view of the trial’s acceptability, either positive or negative. For 464 
others, participation appeared to involve passive acceptance of requests or 465 
instructions rather than active decision making and assessment of trial benefits and 466 
risks. For example, one mother who had not expected the blood samples and did not 467 
understand their purpose explained that she did not question these procedures: 468 
I was not thinking of anything, I just take it as the way it is supposed to be, I can’t 469 
stop the doctor. (Mother, participant, ID02) 470 
While partly indicating a context of unequal power relations between researchers or 471 
health workers and the community within Malawi (Jones et al., 2013), this passive 472 
acceptance also reflected unquestioning trust in researchers (seen as health 473 
workers) as having superior knowledge. Another mother explained that her 474 
participation was voluntary – “they even said it is not something they are forcing us 475 
to do” – but her agreement appeared to follow an assumption that whatever 476 
researchers wanted must be appropriate: 477 
They are the doctors, so if that’s what they think, it’s good to do it like that. … 478 
There wasn’t a reason to ask them why or to caution them, they are the ones who 479 
know and that was the procedure they came with. (Mother, participant, ID05) 480 
 481 
These experiences demonstrate participation and non-participation based on 482 
mistakes in timing, pressure from others, a sense of obligation or passive 483 
agreement; taking part did not always result from a positive view of study 484 
procedures, and not participating did not always mean seeing the trial negatively.  485 
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  486 
 487 
Discussion 488 
 489 
The experiences and views of parents invited to enrol their children in the vaccine 490 
trial indicate multiple variations in perceived acceptability. Some were enthusiastic, 491 
while others took part reluctantly; parents liked some aspects of the trial but not 492 
others; views of the trial changed over time as experiences or information changed; 493 
parents saw the trial positively or negatively because of ideas about what would 494 
happen that did not match actual procedures; and views varied between villages and 495 
individuals. For some who took part, ‘acceptance’ involved a feeling of pressure or 496 
misunderstanding followed by regret, and not participating sometimes reflected lack 497 
of permission from relatives or simply arriving too late, rather than hostility to the trial. 498 
 499 
This variable and context-dependent nature of acceptability echoes findings from 500 
other trials and ethics guidelines. Although these findings and guidelines do not 501 
explicitly examine the concept of acceptability, they suggest the dimensions of 502 
variation described for this trial in Malawi are found more widely. For example, in 503 
relation to varied levels of acceptability, work in The Gambia, Kenya and UK 504 
suggests a mix of positive and negative feelings among both those who do and do 505 
not participate (Fairhead et al., 2004; Gikonyo et al., 2008; Snowdon, 2005), with 506 
some participants experiencing anxiety and alienation (Moynihan et al., 2012). Ethics 507 
guidelines also suggest people may consent to studies they find upsetting, noting a 508 
“cultural tendency to deny or tolerate pain and suffering” as potentially making 509 
women vulnerable in research (CIOMS, 2016, p. 69).  510 
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 511 
In relation to what people find acceptable, several benefits and disadvantages 512 
perceived by invited participants for this vaccine trial are reported for other research, 513 
including appreciation of access to health care or material compensation, and 514 
concerns around blood samples (Fisher et al., 2011; Mfutso-Bengo et al., 2008, 515 
2015; Masiye et al., 2008). Those invited to enrol weigh up these perceived benefits 516 
and risks (Fairhead et al., 2004; Fisher et al., 2011). More generally, an 517 
understanding of trials as having welcome and undesirable aspects is reflected in the 518 
emphasis on benefits, risks and burdens within ethics guidance (Emanuel et al., 519 
2004; Nuffield Council on Bioethics, 2015). The role of rumours and misinformation 520 
or misunderstanding about trial processes is also widely documented (Kingori et al., 521 
2010; Mitchell et al., 2002; Munalula-Nkandu et al., 2015; Ndebele et al., 2014). 522 
Misunderstanding may reflect the content and communication of trial information, but 523 
participants’ experiences and interests also affect their interpretations, and decisions 524 
may involve assumptions and intuitive judgements rather than informed deliberation 525 
(Abhyankar et al., 2016; Woolfall et al., 2013).   526 
  527 
The idea that acceptability changes over time is evident in reports of withdrawal from 528 
trials, for example in response to apparent side effects, new information or changing 529 
personal situations (Gikonyo et al., 2008; Gillies and Entwistle, 2012). Again ethics 530 
guidelines acknowledge this potential for changing views , here in relation to consent 531 
as an ongoing process and the right to withdrawal (CIOMS, 2016).  532 
 533 
Existing literature also shows the influence of context on acceptability. In particular, 534 
research in many low income countries suggests poverty and inadequate health 535 
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services mean research becomes an opportunity to access care (Ravinetto et al., 536 
2015), an influence highlighted in the idea of an ‘empty choice’ (Kingori, 2015). 537 
Variations in acceptability between individuals are also widely documented, including 538 
the influence of gender, a child’s health and previous research experience (Fisher et 539 
al., 2011; Kamuya et al., 2015; Mfutso-Bengo et al., 2008), as well as the 540 
heterogeneity of research communities more generally (Marsh et al., 2011). Ethics 541 
guidelines also discuss this role of context, including study procedures, individual 542 
and household factors, and political and social environments (Nuffield Council on 543 
Bioethics, 2002). 544 
 545 
Finally, previous research also supports a distinction between participation and 546 
acceptability of study procedures. In particular, research in Malawi and other settings 547 
shows the influence of pressure from relatives and chiefs and of competing 548 
employment obligations, such that decisions on participation reflect more than 549 
individual views of study benefits and burdens (Angwenyi et al., 2014; Fairhead et 550 
al., 2004; Magazi et al., 2014; Marsh et al., 2011; Mfutso-Bengo et al., 2008). 551 
Unquestioning faith in researchers and the role of blind trust in generating 552 
acceptability are also described in other contexts (Marsh et al., 2011), partly linked to 553 
conflated researcher and clinician roles and the influence of dependent trust on 554 
healthcare decisions more generally (Gilson, 2003; Molyneux et al., 2005). Limited 555 
understanding of the right to withdraw is also widespread (Afolabi et al., 2014). In 556 
line with these findings, theoretical discussions of research ethics note that 557 
participation “may be based on reluctant acquiescence rather than on enthusiastic 558 
co-operation” (Social Research Association, 2003, p. 29), while non-participation 559 
may result from other priorities rather than negative views of research (Hammersley, 560 
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2017).  561 
    562 
Acceptability, then, varies in degree, between trial components, over time, and 563 
between people and places. One possible reaction is to abandon acceptability to 564 
potential participants as a principle for ethical research, as argued by some who see 565 
acceptability as too hard to define and dependent on social position to be a useful 566 
consideration (Hammersley, 2017; Hunter, 2017; Macdonald, 2017). Acceptability 567 
alone does not make a study ethical; for example high compensation might increase 568 
satisfaction but create undue inducement, and acceptability is one principle to 569 
consider alongside criteria such as scientific validity and social value (Emanuel et al., 570 
2004). Nevertheless, we suggest the idea of acceptability remains useful in drawing 571 
attention to perceptions and experiences among potential participants. However, the 572 
variability documented here raises questions about how we define and assess 573 
acceptability. Should we only consider a trial acceptable if everyone in a community 574 
is enthusiastic about all aspects of the trial, throughout the trial and afterwards, 575 
regardless of their socio-economic circumstances, or should ‘acceptable’ simply 576 
mean there are sufficient participants to meet recruitment targets? Should a trial be 577 
considered ethical if participants are unhappy about their experience, as long as they 578 
made an informed and voluntary decision to participate?  579 
 580 
Given the difficulty of defining a common standard above which trials are considered 581 
acceptable, a more productive focus may be the nature of insights produced through 582 
acceptability research. We suggest that researchers examining acceptability might 583 
first, clarify their definition of acceptable and any associated benchmarks to avoid 584 
ambiguity, and second, provide nuanced descriptions by examining how and why 585 
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acceptability varies among potential participants. This two-fold approach seems 586 
more likely to enable understanding of acceptability and a trial design that responds 587 
to community concerns. The appropriate definition and benchmarks of acceptability 588 
will depend on the context and aim of assessment, for example, whether the aim is 589 
understanding initial participation or longer trial experiences. However, useful ideas 590 
can be drawn from work on vaccine acceptability. In a parallel to the gradient of 591 
positive and negative views and distinction between participation and approval found 592 
in our work, vaccine researchers describe a continuum of vaccine hesitancy and 593 
note that failure to be vaccinated may reflect diverse situations, such as 594 
procrastination rather than active concern (Hickler et al., 2017; Peretti-Watel et al., 595 
2015; SAGE Working Group on Vaccine Hesitancy, 2014). Based on this 596 
understanding, some frameworks on vaccine acceptability distinguish attitudes from 597 
behaviour, and look beyond uptake to a range of actions in support of vaccines, such 598 
as seeking or advocating vaccination (Hickler et al., 2017; Peretti-Watel et al., 2015). 599 
In the context of research participation, a similar approach might involve 600 
investigating levels of satisfaction with the trial to clarify whether participation 601 
involves reluctant tolerance or unequivocal enthusiasm, and identifying behaviour 602 
such as taking part initially, remaining in the trial, or encouraging others to 603 
participate. Some assessments of trial acceptability incorporate elements of this 604 
approach. For example, research on an HIV trial asked participants whether they 605 
were glad to have joined the study, intended to remain in the study, and whether 606 
they were interested in joining future trials (Gafos et al., 2017). This approach avoids 607 
the potentially misleading use of participation as a proxy for acceptability, and 608 
elucidates different degrees of acceptance. 609 
 610 
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On the second step of examining how and why acceptability varies, our work 611 
revealed variations in how acceptable the trial was, what was acceptable, when, in 612 
what circumstances, to whom and why. Describing these variations and examining 613 
reasons behind both perceived acceptability and levels of participation can provide 614 
more in-depth understanding of participant views that avoids concealing ethically 615 
significant details, such as enthusiasm based on misconceptions or participation 616 
based on pressure (either of which would suggest gaps in informed, voluntary 617 
consent). Examining these dimensions of acceptability can also suggest ways to 618 
adapt trial procedures to enhance ethical practice. For example, misconceptions of 619 
trial benefits or declining acceptability as people gain new information might suggest 620 
consent processes need revising to increase awareness of trial procedures and 621 
enable more informed decisions on enrolment (for example through ensuring 622 
information is framed to promote active decision making and addresses parents’ 623 
priorities (Abhyankar et al., 2016; Woolfall et al., 2013)). Participation based on 624 
pressure from others may indicate a need to reemphasise voluntary decisions in 625 
fieldworker training and community engagement, or to address other constraints on 626 
choice identified by participants (Bull and Lindegger, 2011). Discovering that people 627 
are taking part reluctantly or regret joining, and knowing which aspects people 628 
dislike, could help researchers adapt procedures in ways that encourage uptake and 629 
improve participant experiences, reducing unnecessary burden. Variations between 630 
contexts or groups might suggest ways to tailor procedures to different situations. 631 
Finally, if participation reflects limited options for healthcare, research institutions 632 
could engage in longer-term work to enhance access (Kingori, 2015). Community 633 
consultation could help design appropriate responses to such findings 634 
(UNAIDS/AVAC, 2011). 635 
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 636 
While identifying these variations in acceptability can indicate ways to strengthen trial 637 
design, there remain questions around the level of acceptability required for ethical 638 
practice, and about how to make standardised trial designs responsive when 639 
individual views vary. One proposed solution is the idea that ethics committees 640 
should decide whether research constitutes a ‘fair offer’, with participation involving a 641 
fair balance of benefits, burdens and risks (Nuffield Council on Bioethics, 2015). 642 
People invited to take part will make individual decisions that reflect their priorities 643 
and contexts, and may feel participation is unsatisfactory. However, by judging 644 
studies to constitute a fair offer, ethics committees provide a level of protection and 645 
reduce risks of exploitation due to limited choices among participants. Stakeholder 646 
involvement can help ethics committees determine what constitutes a fair offer 647 
(Nuffield Council on Bioethics, 2015).  648 
  649 
Our research had limitations. Further interviews and extended participant 650 
observation across additional study villages might have deepened understanding of 651 
participant perceptions and contextual variation. We initially planned to interview 652 
more parents who did not participate or who withdrew, but these households were 653 
harder to identify, partly because overall trial participation was high and 654 
approximately 90% of those who did participate remained in the trial. Additional 655 
repeat interviews might have increased information on changing perceptions, 656 
particularly for those who withdrew. However, it was not possible to identify parents 657 
who would later withdraw in advance, and interviewing enough initial participants to 658 
obtain an adequate sample of later withdrawals was unfeasible. In addition, the 659 
repeat interviews that were conducted did not produce substantially different data, 660 
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leading us to decide against further repeat visits. Parents interviewed at later stages 661 
of the trial or after withdrawal described changes in their views, helping us to 662 
understand shifting perceptions without repeat interviews. Towards the end of data 663 
collection, similar themes were recurring within each group of interviewees 664 
(participants, non-participants and those who withdrew), suggesting that additional 665 
interviews were unlikely to produce significantly new ideas. 666 
 667 
Conducting research alongside the trial posed challenges for relationship with trial 668 
staff and parents. As we came from the same research institution as the trial team 669 
and sometimes shared transport with them, parents might have been reluctant to 670 
speak openly. During observation, some trial staff were concerned we would monitor 671 
their activities, which may have led them to behave differently. During interviews and 672 
observation, we emphasised to parents and community members that we were not 673 
part of the trial, did not want to check or encourage their participation, and would not 674 
share information on individuals with trial staff. With trial staff, we emphasised that 675 
we were not checking procedures and would not report individual comments or 676 
behaviour to supervisors. Critical comments about the trial from both parents and 677 
trial staff suggest some success in building rapport and encouraging openness. 678 
However, the possibility of influencing responses was considered during analysis. 679 
 680 
 681 
Conclusion 682 
The idea that research should be acceptable to potential participants is ambiguous 683 
and complex. Being specific about what is meant by acceptability (for example, 684 
agreement to participate, or satisfaction with all trial procedures), and considering 685 
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how and why acceptability varies, could provide a more nuanced picture of 686 
acceptability that enables identification of ethical gaps and responsive trial design. 687 
  688 
The six dimensions of acceptability described in this article - how much, what, when, 689 
under what circumstances, to whom and why – provide one set of possible areas to 690 
consider in examining acceptability. Future research could examine the value of 691 
these dimensions or other frameworks for understanding acceptability, as well as the 692 
strengths and weaknesses of different empirical methods for exploring community 693 
views.  694 
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Six dimensions of research trial acceptability: how much, what, when, in what 
circumstances, to whom and why?  
 
Research highlights  
• Highlights ambiguity in the idea that research must be acceptable to invited 
participants 
• Examines acceptability of a trial to parents invited to enrol their children  
• Indicates differences between giving consent and seeing a trial as acceptable  
• Acceptability varies in degree and between times, components, contexts and 
people  
• Suggests six dimensions of variation as a guide for future acceptability research 
 
 
